Drugs by condition
Drugs approved for gaucher disease
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
5
Still marketed, NDA or BLA
Drug classes
2
Novel drugs
5
New molecular entities and new biologics
In development
2
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for gaucher disease.
- Cerdelga (Eliglustat Tartrate) · Genzyme Corp NovelPriority reviewOrphanAug 19, 2014
- Elelyso (Taliglucerase Alfa) · Pfizer NovelOrphanMay 1, 2012
- Vpriv (Velaglucerase Alfa) · Shire Human Genetic NovelPriority reviewOrphanFeb 26, 2010
- Zavesca (Miglustat) · Actelion NovelOrphanJul 31, 2003
- Cerezyme (Imiglucerase) · Genzyme NovelPriority reviewOrphanMay 23, 1994
All approved drugs for gaucher disease, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 3 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Hydrolytic Lysosomal Glucocerebroside-specific Enzyme (3)
Glucosylceramide Synthase Inhibitor (2)
Drugs in development for gaucher disease
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- NizubaglustatAZ-3102Phase 36 trials
Azafaros B.V. · Niemann-Pick Type C Disease, GM2 Gangliosidosis, GM1 Gangliosidosis
- VenglustatGZ402671Phase 35 trials
Sanofi · Fabry Disease, Gaucher's Disease Type III, Gaucher Disease Type 1
More on gaucher disease: recruiting trials · published research
Related in rare and genetic disease: Transthyretin amyloidosis · Hereditary angioedema · Fabry disease · Pompe disease · Phenylketonuria (PKU) · Achondroplasia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.